Notícias Merck and Co Inc - MRK | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Merck and Co Inc (MRK)
Merck and Co Inc (MRK) Notícias

Merck and Co Inc (MRK)

98,05

-1,47

(-1,48%)

Fechado 22 Dezembro 6:00PM

Atrasado por 15 minutos

98,99

0,94

(0,96%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck se posiciona no mercado da obesidade ao licenciar medicamento experimental com Hansoh Pharma

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations

Merck to Participate in the Citi 2024 Global Healthcare Conference

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

MFE MediaForEurope

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições